Spinal Elements Announces First Clinical Use of the Lucent® 3D Lumbar Interbody System

Spinal Elements, a spine technology company, today announced that the Lucent 3D Lumbar Interbody System has been successfully used in its first clinical cases with Dr. Thomas Noh, Neurosurgeon at Hawaii Pacific Health and Assistant Clinical Professor at the John A. Burns School of Medicine (JABSOM) at the University of Hawaii and Dr. Douglas H. Musser, D.O. at Youngstown Orthopedics Associates in Canfield, Ohio.

The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence. The resulting Lucent 3D implant is comprised of a strut-and-lattice structure with a bone graft chamber access lid designed to allow the surgeon to deliver a large amount of tightly packed graft inside the interbody structure, maximizing the amount of graft material available for fusion. Furthermore, when the access lid to the graft chamber is closed, the lid is designed to maximize surface area in contact with the vertebral endplates. Provided in both straight and curved designs, the interbody device is designed to be placed through an open or MIS posterior approach.

Dr. Noh commented, “The Lucent 3D Interbody is a novel and useful surgical option in my practice. The curved implant was easy to insert and helped to maintain lordosis. Knowing that there is tightly packed graft inside the cage provides additional confidence that a successful fusion will occur.”

Jason Blain, CEO of Spinal Elements, stated, “We are thrilled to share this technology with the surgical community. Lucent 3D’s novel design is meant to address subsidence and the amount of bone graft material available for fusion – two clinical challenges surgeons note exist with other 3D-printed interbody devices. We are pleased to offer additional innovative titanium interbody devices to our expansive and best-in-class product portfolio, adding to our long tradition of innovation in material science, novel designs, and leadership. We truly can answer any need for posterior lumbar fusion and continue to build on our procedural solutions.”

After finishing his first several Lucent 3D cases, Dr. Musser commented, “The design and structure of the Lucent 3D cage have provided a biologic containment area that has enabled me to place more graft material than traditional PLIF and TLIF cages. The Lucent 3D cage also has excellent visualization on both A/P and Lateral views when using fluoroscopy.”

Spinal Elements announced FDA clearance of the Lucent 3D system in April of this year and expects to expand on Lucent 3D’s graft containment concept in other clinical applications.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy